Cite
HARVARD Citation
Hallmeyer, S. et al. (2017). Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma research. 27 (6), p. . [Online].